| Name | Izeltabart |
|---|
| Description | Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. Izeltabart is comprised of a high-affinity humanized antibody site-specifically conjugated to DM21-C, a linker-payload that combines a Maytansinoid microtubule-disrupting payload with a stable tripeptide linker, at a drug antibody ratio of approximately 2.0. Izeltabart exhibits cytotoxicity toward ADAM9-positive human tumor cell lines and has potent antitumor activity in xenograft tumor models[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |